NodThera, a decade-old biotech focused on the NLRP3 inflammasome pathway, announced plans for pivotal Phase 3 trial development beginning in 2027 along with a corporate rebrand. The company said its program is entering the most capital-intensive stage of development after years of preclinical and earlier clinical investment in NLRP3 biology, which remains a highly pursued anti-inflammatory mechanism. Coverage framed the plan as a clear signal that NodThera is attempting to translate a long-running pathway thesis into late-stage clinical execution, typically requiring tighter timelines, manufacturing scale-up, and confirmatory efficacy evidence. The rebrand to Rezera also aims to reset positioning as the company moves closer to registrational milestones.